<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023486</url>
  </required_header>
  <id_info>
    <org_study_id>NP-G2-044-P2-01</org_study_id>
    <nct_id>NCT05023486</nct_id>
  </id_info>
  <brief_title>NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies</brief_title>
  <official_title>NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novita Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novita Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label study in patients with advanced or metastatic solid tumor&#xD;
      malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK,&#xD;
      and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination&#xD;
      with anti-PD-(L)1 therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy</measure>
    <time_frame>Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)</time_frame>
    <description>Will use NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1</measure>
    <time_frame>24 months</time_frame>
    <description>(computed tomography [CT] or magnetic resonance imaging [MRI])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-(L)1 therapy</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-(L)1 combination therapy</measure>
    <time_frame>Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)</time_frame>
    <description>Will use NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-(L)1 therapy assessed by RECIST 1.1</measure>
    <time_frame>24 months</time_frame>
    <description>(computed tomography [CT] or magnetic resonance imaging [MRI])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify and characterize preliminary anti-tumor activity of NP-G2-044 in combination with anti-PD-(L)1 therapy</measure>
    <time_frame>24 months</time_frame>
    <description>Anti-tumor activity assessed using iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of NP-G2-044 monotherapy: AUC</measure>
    <time_frame>6 months</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of NP-G2-044 monotherapy: Tmax</measure>
    <time_frame>6 months</time_frame>
    <description>Time to peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of NP-G2-044 monotherapy: Cmax</measure>
    <time_frame>6 months</time_frame>
    <description>Peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of NP-G2-044 and anti-PD-(L)1 Combination therapy: AUC</measure>
    <time_frame>9 months</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of NP-G2-044 and anti-PD-(L)1 Combination therapy: Tmax</measure>
    <time_frame>9 months</time_frame>
    <description>Time to peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of NP-G2-044 and anti-PD-(L)1 Combination therapy: Cmax</measure>
    <time_frame>9 months</time_frame>
    <description>Peak plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced or Metastatic Solid Tumor Malignancies</condition>
  <arm_group>
    <arm_group_label>NP-G2-044 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP-G2-044 capsule PO QD for each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP-G2-044 Combination Therapy With Anti-PD-(L)1 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NP-G2-044 capsule PO QD for each 28-day cycle, Anti-PD-(L)1 Therapy per standard of care, at a dose and frequency in accordance with the package insert</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP-G2-044 Monotherapy</intervention_name>
    <description>1600 mg QD and 2100 mg QD</description>
    <arm_group_label>NP-G2-044 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-PD-(L)1 Therapy</intervention_name>
    <description>previously initiated per standard of care, at a dose and frequency in accordance with the package insert</description>
    <arm_group_label>NP-G2-044 Combination Therapy With Anti-PD-(L)1 Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NP-G2-044 Combination therapy</intervention_name>
    <description>1200 mg QD or 1600 mg QD - starting dose</description>
    <arm_group_label>NP-G2-044 Combination Therapy With Anti-PD-(L)1 Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18 years of age;&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;&#xD;
&#xD;
          3. Life expectancy of &gt;6 months;&#xD;
&#xD;
          4. Able to swallow capsules;&#xD;
&#xD;
          5. Adequate organ and bone marrow function, defined by the following:&#xD;
&#xD;
             ANC &gt;1500 cells/μL; Hemoglobin &gt;9.0 g/dL; Platelet count &gt;100,000 cells/μL; Total&#xD;
             bilirubin ≤1.5 mg/dL; Albumin ≥3.0 g/dL; Alanine aminotransferase, aspartate&#xD;
             aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase ≤2.5 × upper&#xD;
             limit of normal (ULN); Serum creatinine ≤1.5 mg/dL and creatinine clearance ≥60&#xD;
             mL/min/1.73 m2; and Prothrombin time and partial thromboplastin time ≤1.5 × ULN.&#xD;
&#xD;
          6. Female patients of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test at Screening and within 72 hours before the first dose of NP-G2-044. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required and must be negative for the patient to be eligible; Note: A woman is&#xD;
             considered of childbearing potential unless she is postmenopausal (≥1 year without&#xD;
             menses and confirmed with a follicle-stimulating hormone [FSH] test) or surgically&#xD;
             sterilized via bilateral oophorectomy, hysterectomy, bilateral tubal ligation, or&#xD;
             successful Essure® placement with a documented confirmation test at least 3 months&#xD;
             after the procedure.&#xD;
&#xD;
          7. Male patients must be surgically sterile or willing to use a highly effective&#xD;
             double-barrier contraception method (eg, male condom with diaphragm or male condom&#xD;
             with cervical cap) upon study entry, while on NP-G2-044, and for a period of at least&#xD;
             4 months following the last dose of NP-G2-044; and&#xD;
&#xD;
          8. Able to understand and voluntarily sign a written informed consent form (ICF) and&#xD;
             willing and able to comply with protocol requirements.&#xD;
&#xD;
        Inclusion Criteria for NP-G2-044 Monotherapy:&#xD;
&#xD;
        Patients must meet all the following criteria to receive NP-G2-044 monotherapy in the&#xD;
        study:&#xD;
&#xD;
          1. Have a histopathologically confirmed advanced or metastatic solid tumor malignancy&#xD;
             that is either treatment-refractory or otherwise ineligible for treatment with&#xD;
             standard of care agents/regimens; and&#xD;
&#xD;
          2. Have measurable disease per RECIST 1.1.&#xD;
&#xD;
        Inclusion Criterion for NP-G2-044 Combination Therapy Patients must meet the following&#xD;
        criterion to receive NP-G2-044 in combination with anti-PD-(L)1 therapy in the study:&#xD;
&#xD;
        1. Have initiated anti-PD-(L)1 therapy in accordance with the package insert and have been&#xD;
        receiving the anti-PD-(L)1 therapy for ≥3 months (and therapy is currently ongoing) and&#xD;
        have stable disease, or had an initial period of stable disease and now have an initial&#xD;
        scan demonstrating progressive disease per RECIST 1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received chemotherapy or radiotherapy within 4 weeks or 5 half-lives, whichever is&#xD;
             shorter, of the first dose of NP-G2-044; Note: Prior immunotherapy is allowed for&#xD;
             patients receiving NP-G2-044 monotherapy.&#xD;
&#xD;
          2. Unresolved toxicities from previous anti-cancer therapy, defined as toxicities (other&#xD;
             than NCI CTCAE v5.0 Grade ≤2 alopecia or neuropathy) not yet resolved to NCI CTCAE&#xD;
             v5.0 Grade ≤1; Note: Patients who experienced a Grade ≥3 anti-PD-(L)1-related AE per&#xD;
             NCI CTCAE v5.0 are excluded unless recovered and reviewed by the Novita Medical&#xD;
             Monitor or designee.&#xD;
&#xD;
          3. Receiving any other investigational agent(s) or have received an investigational agent&#xD;
             within 4 weeks of the first dose of NP-G2-044;&#xD;
&#xD;
          4. Known untreated brain metastases or treated brain metastases that have not been&#xD;
             radiographically and clinically stable (ie, not requiring steroids) ≥4 weeks prior to&#xD;
             study enrollment;&#xD;
&#xD;
          5. QTc by Fridericia method &gt;470 msec or electrocardiogram (ECG) with evidence of&#xD;
             clinically meaningful conduction abnormalities or active ischemia as determined by the&#xD;
             Investigator;&#xD;
&#xD;
          6. Uncontrolled intercurrent illness including, but not limited to, symptomatic&#xD;
             congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia,&#xD;
             autoimmune or inflammatory diseases, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements;&#xD;
&#xD;
          7. Pregnant, lactating, has been pregnant within the last 2 years, or is planning to&#xD;
             attempt to become pregnant or impregnate someone during the study or within 90 days&#xD;
             after dosing of NP-G2-044;&#xD;
&#xD;
          8. Received prior allogenic hematopoietic stem cell transplantation or allogenic bone&#xD;
             marrow transplantation;&#xD;
&#xD;
          9. Received prior solid organ transplantation;&#xD;
&#xD;
         10. Ongoing immunosuppressive therapy (≥10 mg/day of prednisone or its equivalent);&#xD;
&#xD;
         11. Requires the use of a strong inhibitor or inducer of cytochrome P450 (CYP)3A4, CYP1A2,&#xD;
             or CYP2D6 during the study;&#xD;
&#xD;
         12. History of clinically meaningful gastrointestinal bleeding, intestinal obstruction, or&#xD;
             gastrointestinal perforation within 6 months of study enrollment; or&#xD;
&#xD;
         13. Excluded by the Sponsor due to medical history, physical examination findings,&#xD;
             clinical laboratory results, prior medications, or other entrance criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jillian Zhang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Novita Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelley Arnold</last_name>
    <phone>+1 6159647375</phone>
    <email>K_Arnold@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Stanisz</last_name>
      <phone>480-323-1350</phone>
      <email>nstanisz@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Frank Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aruna Parikh</last_name>
      <phone>626-218-3419</phone>
      <phone_ext>83419</phone_ext>
      <email>arparikh@coh.org</email>
    </contact>
    <investigator>
      <last_name>Vincent Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced or Metastatic Solid Tumor Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

